Physician profile
Bobby N Johnson
NPI 1285683649
$4,124.19
in general payments reported to CMS, 2019-2025
23 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $982 · 2021: $204 · 2022: $584 · 2023: $813 · 2024: $820 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.07 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $856.26 | 2021-2025 | Minimed 780g, Minimed 770g |
| Tandem Diabetes Care, INC. | $850.00 | 2020 | |
| Dexcom, INC. | $660.49 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $648.08 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $278.32 | 2021-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $187.63 | 2022-2025 | Gvoke Hypopen |
| Medtronic Minimed, INC. | $132.12 | 2020 | |
| Lilly USA, LLC | $72.26 | 2023-2025 | Jardiance, Mounjaro, Humulin |
| Beta Bionics, INC. | $72.12 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $61.84 | 2025 | |
| Sanofi-Aventis U.S. LLC | $48.71 | 2024 | |
| Amgen INC. | $38.50 | 2025 | Tepezza, Repatha |
| Corcept Therapeutics | $33.65 | 2022-2024 | Korlym |
| Chiesi USA, INC. | $27.71 | 2025 | Mycapssa |
| Neurocrine Biosciences, INC. | $24.04 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.12 | 2023 | |
| Ascendis Pharma Endocrinology INC | $18.46 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $18.15 | 2023 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $17.82 | 2023 | |
| Insulet Corporation | $16.96 | 2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $14.78 | 2024 | Unithroid |
| Ibsa Pharma INC. | $13.03 | 2023 | Tirosint, Licart |
| Abbvie INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.